Calla Lily Clinical Care Raises £1M to Revolutionize Vaginal Drug Delivery

Calla Lily Clinical Care is excited to announce that the company has successfully raised £1,000,000 in new funding, marking an important milestone in its journey to revolutionize vaginal drug delivery. This dynamic British medical device startup is dedicated to developing a leak-free, convenient, and dosage-confident delivery platform that redefines how patient care is approached in the realm of vaginally-delivered drugs. With this new capital injection, Calla Lily Clinical Care is poised to accelerate the development of its cutting-edge technology, which has already garnered significant accolades, including FDA clearance and recognition as one of TIME magazine’s Best Inventions of the Year. The funding comes at a crucial time, as the company is focusing on addressing the unmet needs within the fertility and reproductive health space. Currently, Calla Lily Clinical Care is prioritizing the delivery of progesterone—a hormone essential for miscarriage prevention and supporting IVF treatments. This innovative solution is designed to provide a more patient-friendly experience during what is often an emotionally challenging fertility journey, particularly in light of the heightened demand following the November 2021 update to NICE’s internationally-renowned guidance on miscarriages. Beyond its initial applications, the company is also exploring further therapeutic areas, including treatments for menopause and interventions aimed at improving the vaginal microbiome, promising broader impacts on women’s health. This investment not only reaffirms the market's confidence in Calla Lily Clinical Care’s technology but also underscores the pressing need for improved drug delivery systems in sensitive areas of healthcare. With the new funding, the company is well positioned to further advance its research and development efforts, ultimately enhancing patient outcomes and redefining standards of care in the industry.